...
首页> 外文期刊>The biochemical journal >Quantification of active mitochondrial permeability transition pores using GNX-4975 inhibitor titrations provides insights into molecular identity
【24h】

Quantification of active mitochondrial permeability transition pores using GNX-4975 inhibitor titrations provides insights into molecular identity

机译:使用GNX-4975抑制剂滴定对活性线粒体通透性过渡孔进行定量分析,可提供分子鉴定的见解

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Inhibition of the mitochondrial permeability transition pore (MPTP) by the novel inhibitor GNX-4975 was characterized. Titration of MPTP activity in de-energized rat liver mitochondria allowed determination of the number of GNX-4975-binding sites and their dissociation constant ( K i). Binding sites increased in number when MPTP opening was activated by increasing [Ca2+], phenylarsine oxide (PAO) or KSCN, and decreased when MPTP opening was inhibited with bongkrekic acid (BKA) or ADP. Values ranged between 9 and 50?pmol/mg of mitochondrial protein, but the K i remained unchanged at ~1.8?nM when the inhibitor was added before Ca2+. However, when GNX-4975 was added after Ca2+ it was much less potent with a K i of ~140?nM. These data imply that a protein conformational change is required to form the MPTP complex and generate the GNX-4975-binding site. Occupation of the latter with GNX-4975 prevents the Ca2+ binding that triggers pore opening. We also demonstrated that GNX-4975 stabilizes an interaction between the adenine nucleotide translocase (ANT), held in its ‘c’ conformation with carboxyatractyloside (CAT), and the phosphate carrier (PiC) bound to immobilized PAO. No components of the F1Fo-ATP synthase bound significantly to immobilized PAO. Our data are consistent with our previous proposal that the MPTP may form at an interface between the PiC and ANT (or other similar mitochondrial carrier proteins) when they adopt novel conformations induced by factors that sensitize the MPTP to [Ca2+]. We propose that GNX-4975 binds to this interface preventing a calcium-triggered event that opens the interface into a pore.* ANT, : adenine nucleotide translocase; BKA, : bongkrekic acid; CAT, : carboxyatractyloside; CsA, : cyclosporin A; CyP-D, : cyclophilin D; IMM, : inner mitochondrial membrane; ISB, : isolation buffer; MCF, : mitochondrial carrier family; MPTP, : mitochondrial permeability transition pore; NTA, : nitrilotriacetic acid; PAO, : phenylarsine oxide; PCB, : PAO column buffer; PEG, : polyethylene glycol; PiC, : phosphate carrier; SPG7, : spastic paraplegia 7
机译:表征了新型抑制剂GNX-4975对线粒体通透性过渡孔(MPTP)的抑制作用。断电的大鼠肝线粒体中MPTP活性的滴定可以确定GNX-4975结合位点的数量及其解离常数(K i)。当通过增加[Ca2 +],苯砷氧化物(PAO)或KSCN激活MPTP开放时,结合位点数量增加,而当用邦克里奇酸(BKA)或ADP抑制MPTP开放时,结合位点数量减少。线粒体蛋白的值在9至50µpmol / mg之间,但当在Ca2 +之前加入抑制剂时,K i保持在〜1.8µnM不变。但是,当在Ca2 +之后加入GNX-4975时,其Ki约为140?nM的效力要低得多。这些数据表明形成MPTP复合物并生成GNX-4975结合位点需要蛋白质构象变化。后者被GNX-4975占用会阻止Ca2 +结合,从而触发开孔。我们还证明了GNX-4975可稳定与羧基白术苷(CAT)保持其“ c”构型的腺嘌呤核苷酸转位酶(ANT)和与固定化PAO结合的磷酸盐载体(PiC)之间的相互作用。 F1Fo-ATP合酶的任何成分均不与固定的PAO显着结合。我们的数据与我们先前的建议一致,即当MPTP采用由MPTP对[Ca2 +]敏感的因子诱导的新构象时,可能在PiC和ANT(或其他类似的线粒体载体蛋白)之间的界面上形成MPTP。我们建议GNX-4975结合到该界面上,以防止发生钙触发事件,从而将界面打开到毛孔中。 BKA ,:邦克里奇酸; CAT ,:羧基白术苷; CsA ,:环孢菌素A; CyP-D ,:亲环蛋白D; IMM:线粒体内膜; ISB:隔离缓冲区; MCF ,:线粒体携带者家族; MPTP:线粒体通透性过渡孔; NTA ,:次氮基三乙酸; PAO:苯ar氧化物; PCB :: PAO列缓冲; PEG ,:聚乙二醇; PiC:磷酸盐载体; SPG7:痉挛性截瘫7

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号